CO6511276A2 - Composición probiótica para uso en el tratamiento de la inflamación del intestino - Google Patents

Composición probiótica para uso en el tratamiento de la inflamación del intestino

Info

Publication number
CO6511276A2
CO6511276A2 CO12125095A CO12125095A CO6511276A2 CO 6511276 A2 CO6511276 A2 CO 6511276A2 CO 12125095 A CO12125095 A CO 12125095A CO 12125095 A CO12125095 A CO 12125095A CO 6511276 A2 CO6511276 A2 CO 6511276A2
Authority
CO
Colombia
Prior art keywords
treatment
intestine
inflammation
probiotic composition
cect
Prior art date
Application number
CO12125095A
Other languages
English (en)
Spanish (es)
Inventor
Mazo Jordi Espadaler
Castellana Jordi Cune
Original Assignee
Ab Biotics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Biotics Sa filed Critical Ab Biotics Sa
Publication of CO6511276A2 publication Critical patent/CO6511276A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3204Probiotics, living bacteria to be ingested for action in the digestive tract
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/11Lactobacillus
    • A23V2400/169Plantarum
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/41Pediococcus
    • A23V2400/413Acidilactici
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells
    • A61K2035/115Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CO12125095A 2010-01-28 2012-07-25 Composición probiótica para uso en el tratamiento de la inflamación del intestino CO6511276A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29911610P 2010-01-28 2010-01-28
EP10151998 2010-01-28

Publications (1)

Publication Number Publication Date
CO6511276A2 true CO6511276A2 (es) 2012-08-31

Family

ID=42243204

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12125095A CO6511276A2 (es) 2010-01-28 2012-07-25 Composición probiótica para uso en el tratamiento de la inflamación del intestino

Country Status (19)

Country Link
US (2) US20130101566A1 (cg-RX-API-DMAC7.html)
EP (1) EP2528610B1 (cg-RX-API-DMAC7.html)
JP (1) JP5777640B2 (cg-RX-API-DMAC7.html)
KR (1) KR101840239B1 (cg-RX-API-DMAC7.html)
CN (1) CN102905712B (cg-RX-API-DMAC7.html)
AU (1) AU2011209407B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012018813B1 (cg-RX-API-DMAC7.html)
CA (1) CA2787544C (cg-RX-API-DMAC7.html)
CL (1) CL2012002062A1 (cg-RX-API-DMAC7.html)
CO (1) CO6511276A2 (cg-RX-API-DMAC7.html)
ES (1) ES2437940T3 (cg-RX-API-DMAC7.html)
MX (1) MX2012008817A (cg-RX-API-DMAC7.html)
MY (1) MY162344A (cg-RX-API-DMAC7.html)
PH (1) PH12012501540A1 (cg-RX-API-DMAC7.html)
PL (1) PL2528610T3 (cg-RX-API-DMAC7.html)
RU (1) RU2563525C2 (cg-RX-API-DMAC7.html)
UA (1) UA109123C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011092261A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201205683B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6033290B2 (ja) * 2011-06-10 2016-11-30 株式会社アモーレパシフィックAmorepacific Corporation チャノキ葉から分離した新規なラクトバチルス・プランタラム
US9579353B2 (en) * 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
JP5995593B2 (ja) * 2012-08-02 2016-09-21 丸善製薬株式会社 抗炎症剤
WO2014096901A1 (en) * 2012-12-18 2014-06-26 Compagnie Gervais Danone Strain of bifidobacterium animalis ssp. animalis
WO2014168474A1 (en) * 2013-04-08 2014-10-16 N.V. Nutricia Fermented nutritional composition with thiol protease inhibitor
SI24570A (sl) 2013-12-23 2015-06-30 Medis D.O.O. Novi sevi rodu Lactobacillus in njihova uporaba
CN106029081A (zh) * 2014-02-28 2016-10-12 株式会社明治 功能性消化道障碍预防和/或改善剂
US10967013B2 (en) * 2014-04-23 2021-04-06 National Yang-Ming University Lactic acid bacterium for prophylaxis or treatment of a stress-induced disorder and a composition containing the same
US10188684B2 (en) * 2015-04-20 2019-01-29 National Yang-Ming University Method for preventing or treating functional gastrointestinal disorder by lactic acid bacterium
PL3223837T3 (pl) * 2014-11-25 2020-06-01 Dsm Ip Assets B.V. Lactobacillus do zastosowania jako probiotyk
JP7330667B2 (ja) * 2014-11-28 2023-08-22 アナジェニックス アイピー リミテッド ゴールドキウイフルーツ組成物ならびにその調製および使用方法
US10195237B2 (en) * 2015-03-16 2019-02-05 Imagilin Technology Llc Compositions and methods for treating inflammatory related diseases or conditions using Pediococcus acidilactici probiotics
US10946050B2 (en) 2015-03-16 2021-03-16 Imagilin Technology Llc Compositions comprising probiotics and methods of use thereof
MA41010B1 (fr) * 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2017062175A1 (en) * 2015-10-06 2017-04-13 Albert Einstein College Of Medicine, Inc. Microbial hyperswarmers and uses thereof
MX2019009079A (es) 2017-01-31 2019-09-26 Univ Industry Cooperation Group Kyung Hee Univ Nuevas bacterias acido lacticas y usos de las mismas.
KR102464397B1 (ko) * 2017-09-15 2022-11-08 (주)아모레퍼시픽 락토바실러스 플란타룸을 포함하는 위장관 질환의 예방 및 개선용 조성물
BR112020015599A2 (pt) 2018-02-02 2021-01-05 Kobiolabs, Inc. Cepa de lactobacillus plantarum kbl396 e uso da mesma
CN112153974A (zh) * 2018-03-15 2020-12-29 南加利福尼亚大学 禁食模仿膳食(fmd)而非仅饮水禁食促进炎症和ibd病理学的逆转
KR102118343B1 (ko) * 2018-07-13 2020-06-03 롯데푸드 주식회사 장 도달력이 우수하고 장내 염증 예방 효과를 가지는 우유와 발효유
AR115757A1 (es) * 2018-07-13 2021-02-24 Cj Cheiljedang Corp Composición que comprende la cepa cjlp475 de lactobacillus plantarum y la cepa cjlp17 de lactobacillus plantarum y el uso de la misma
KR102036275B1 (ko) * 2018-10-02 2019-10-24 서울대학교 산학협력단 항-염증 활성이 우수한 페디오코커스 악시딜락티시 ldtm 5201 신균주(kctc 13563bp)
KR102038695B1 (ko) * 2018-10-30 2019-10-30 주식회사 종근당바이오 프로바이오틱스를 유효성분으로 포함하는 알코올성 장손상 예방 또는 치료용 조성물
US20220054561A1 (en) * 2018-12-14 2022-02-24 The University Of North Carolina At Chapel Hill Lachnospiraceae mitigates against radiation-induced hematopoietic/gastrointestinal injury and death, and promotes cancer control by radiation
KR102094415B1 (ko) * 2018-12-17 2020-03-30 강원대학교산학협력단 프로바이오틱 활성 및 항균활성을 갖는 페디오코커스 애시디락티시 균주
KR102500854B1 (ko) * 2019-12-17 2023-02-17 한국 한의학 연구원 페디오코쿠스 이노피나투스를 유효성분으로 포함하는 숙취해소용 조성물
WO2022171304A1 (en) * 2021-02-12 2022-08-18 Ab-Biotics, S.A. Probiotic composition for the treatment of covid-19
WO2023176849A1 (ja) 2022-03-17 2023-09-21 株式会社カネカ グルクロニダーゼ活性剤、医薬組成物、食用組成物、及び経口用組成物
CN114921351B (zh) * 2022-05-06 2023-06-13 大连工业大学 一株具有益生功能的毕赤酵母菌dpuy-f1及在缓解结肠炎症状中的应用
CN116083277B (zh) * 2022-09-17 2024-02-13 浙江大学 具有缓解溃疡性结肠炎功效的乳酸片球菌zjuids13及其应用
KR20240102112A (ko) * 2022-12-23 2024-07-03 주식회사 씨티씨바이오 대장염 예방 또는 치료활성 및 장내 유해균에 항균활성을 지닌 락토바실러스 및 그의 용도
KR102803865B1 (ko) * 2023-07-31 2025-05-09 전라남도 사료첨가제 및 이를 포함하는 사료 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463796B (sv) 1988-03-09 1991-01-28 Carl Erik Albertsson Foerfarande foer framstaellning av en naeringskomposition och daervid framstaelld naeringskomposition
SE469875C (sv) 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
SE9501056D0 (sv) 1995-03-23 1995-03-23 Probi Ab Epithelial adherent lactobacilli
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
FR2813790B1 (fr) * 2000-09-11 2004-03-12 Dolisos Lab Preparations pharmaceutiques contenant des extraits d'isoflavone de soja et des micro-organismes probiotiques
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
WO2004110466A2 (en) * 2003-06-13 2004-12-23 N.V. Nutricia Pediocin-producing pediococci
AU2004267304B2 (en) * 2003-08-21 2009-03-12 Otsuka Pharmaceutical Co., Ltd. Lactic acid bacteria having mucosal immunopotentiation effect
EP1714660A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
AT501919B1 (de) * 2005-06-14 2008-09-15 Erber Ag Probiotischer, gesundheits- bzw. leistungsfördernder futtermittel- und/oder trinkwasserzusatz für tiere sowie seine verwendung
AU2006297896B2 (en) * 2005-10-06 2011-12-08 Probi Ab Use of lactobacillus for treatment of autoimmune diseases
CA2628495A1 (en) * 2005-11-14 2007-05-18 Unilever Plc Edible product containing ginseng polysaccharides and beneficial bacteria
WO2007150052A1 (en) * 2006-06-23 2007-12-27 Equine Research Associates, Ltd Animal nutritional supplement and method
JP2008013534A (ja) * 2006-07-07 2008-01-24 Health Vision:Kk ペット用プロバイオティクス製品
WO2009112361A2 (en) * 2008-03-14 2009-09-17 Nestec S.A. Synbiotic mixture
WO2010114864A1 (en) * 2009-04-01 2010-10-07 Little Calumet Holdings, Llc Probiotic oral dosage forms
US8298526B2 (en) * 2010-06-02 2012-10-30 Genmont Biotech Inc. Lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof
WO2015021530A1 (en) * 2013-08-12 2015-02-19 Mansel Griffiths Antiviral methods and compositions comprising probiotic bacterial molecules

Also Published As

Publication number Publication date
EP2528610A1 (en) 2012-12-05
ZA201205683B (en) 2013-08-28
AU2011209407B2 (en) 2014-02-27
EP2528610B1 (en) 2013-11-13
UA109123C2 (uk) 2015-07-27
CL2012002062A1 (es) 2013-10-04
ES2437940T3 (es) 2014-01-15
US20160220620A1 (en) 2016-08-04
MX2012008817A (es) 2012-11-23
JP5777640B2 (ja) 2015-09-09
JP2013517784A (ja) 2013-05-20
AU2011209407A1 (en) 2012-09-20
MY162344A (en) 2017-06-15
CA2787544A1 (en) 2011-08-04
KR101840239B1 (ko) 2018-03-20
RU2563525C2 (ru) 2015-09-20
KR20130002372A (ko) 2013-01-08
PH12012501540A1 (en) 2012-10-22
CN102905712A (zh) 2013-01-30
CN102905712B (zh) 2015-12-16
US10155015B2 (en) 2018-12-18
RU2012136615A (ru) 2014-03-10
BR112012018813B1 (pt) 2020-12-08
CA2787544C (en) 2019-07-09
BR112012018813A2 (pt) 2017-06-20
PL2528610T3 (pl) 2014-02-28
US20130101566A1 (en) 2013-04-25
WO2011092261A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
CO6511276A2 (es) Composición probiótica para uso en el tratamiento de la inflamación del intestino
WO2015047941A3 (en) Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
RU2008136876A (ru) Применение bifidobacterium longum для предупреждения и лечения воспаления
PH12013500441A1 (en) Materials and methods for improving gastrointestinal function
IL220613B (en) Use of antibiotics and a probiotic formulation in the preparation of a drug for the treatment of inflammatory bowel disease
PL2571503T3 (pl) Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń
IL291445A (en) Bacterial strains, their compositions and their use for the treatment of gastrointestinal disorders
EA201690147A1 (ru) Пероральные композиции
IN2012DN01638A (cg-RX-API-DMAC7.html)
CL2011001692A1 (es) Composicion farmaceutica que entrega acido butirico y glutamina directamente en el colon, para inducir la liberacion de una hormona intestinal desde celulas l del colon; su uso en diabetes tipo i o tipo ii y obesidad, entre otros.
MX379226B (es) Composiciones y métodos para tratar trastornos metabólicos.
WO2012047631A3 (en) Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
BRPI0906492A2 (pt) antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações
CL2011001939A1 (es) Uso de lactobacillus helveticus cncm i-4095 para apoyar la perdida de peso y/o mantenimiento del peso en humanos y/o animales, particularmente para tratar la obesidad y trastornos metabólicos; y microorganismo de la cepa de lactobacillus helveticus cncm i-4095.
UA113399C2 (xx) Штам непатогенної грамнегативної бактерії та його застосування в дерматології
CL2016000820A1 (es) Diagnóstico y tratamiento del síndrome del intestino irritable y la enfermedad inflamatoria intestinal
PL2457576T3 (pl) Szczep Lactobacillus reuteri do stosowania medycznego i weterynaryjnego w profilaktyce oraz w leczeniu zespołu metabolicznego lub infekcji
EA201291440A1 (ru) Пробиотические штаммы для применения при повышении трансэпителиального сопротивления
ES2711427T8 (es) Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos
CL2011001937A1 (es) Uso de la cepa de lactobacillus rhamnosus cncm i-4096 para apoyar la pérdida de peso y/o mantenimiento del peso en humanos y/o animales, específicamente para el tratamiento de la obesidad.
WO2014011564A3 (en) Compositions and method for treatment and prophylaxis of inflammatory bowel disease
EP2730287A4 (en) USE OF A SALMONELLA FLAGELLIN DERIVATIVE IN THE PREPARATION OF A MEDICAMENT FOR PREVENTING AND TREATING INFLAMMATORY INTESTINAL DISEASES
MX2020009196A (es) Combinacion de lactobacilos para el alivio del sindrome del intestino irritable y para el alivio de otros trastornos gastrointestinales.
CL2009000878A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como dolor, migraña, diabetes, enfermedades del tracto respiratorio, enfermedades intestinales inflamatorias, obesidad, entre otras.